← Back

Wire · opportunities

Erasca Pill Shrinks Tumors in Early Cancer Trial

Published

22 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at wisevoter.com →

◆ Verified

Fusion42 · 22 November 2026 · Fusion42 review

Erasca's daily pill ERAS-0015 showed tumor shrinkage in nearly half of patients with advanced pancreatic and lung cancers in an early-stage trial, with late-stage trials planned for 2027. This drug targets mutant RAS proteins prevalent in many pancreatic cancers, extending promising approaches that have doubled survival time in past studies.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a niche opening in developing oral cancer treatments targeting mutant RAS proteins as ERAS-0015 advances to late-stage trials. The patient market for pancreatic and lung cancer drugs is starting to shift towards oral therapies with promising early results, creating new product demand and trial opportunities.

◆ Coverage

1 source · 22 Nov 2026

◆ Related on Wire

◆ Topics

Biotechcancerdrug-developmentclinical-trialsbiotechmutant-ras